NCT00069511View on ClinicalTrials.gov

12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.

PHASE2UnknownINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

December 31, 2004

Conditions
Hepatitis C
Interventions
DRUG

UT-231B

Trial Locations (6)

23298

VCU/MCV, Richmond

27599

UNC Hospital, Chapel Hill

38120

Memphis Gastroenterology Group, Memphis

70112

Tulane Univ. Health Sciences Center, New Orleans

32610-0214

Shands Hospital at the University of Florida, Gainesville

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY